NCT06830408Completed
Performance of 177Lu-PSMA-I&T for RLT in mCRPC - Prospective Multicenter Swiss Registry Study
Swiss Cancer Registry on Safety and Efficacy of 177Lu-ITG-PSMA-1 Radionuclide Therapy in Prostate Cancer Patients
Source: ClinicalTrials.gov · Last updated 17 Feb 2025
Brief summary (registry, in English)
The goal of this observational study (multicenter, national registry-based) is to evaluate the performance of 177Lu-ITG-PSMA-1 (177Lu-PSMA-I\&T) as therapy in patients with metastatic castration resistent prostate cancer (mCRPC). The main questions are whether the 177Lu-PSMA-I\&T is safe and if it works well to treat patients with progressive mCRPC. The data and information in the study are collected under standard medical therapy and follow-up, so called real-world conditions. Participants will: * undergo regular radioligand therapy (RLT) with 177Lu-PSMA-I\&T * have clinical, laboratory and imaging follow-up according to the currently available recommendation for PSMA-RLT an in line with their medical needs. * answer study related set of questionnaires
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 250 (actual)
- First submitted
- 30 Jan 2025
- Start date
- 6 Jul 2020
- Primary completion date
- 12 Nov 2024
- Lead sponsor
- University Hospital, Basel, Switzerland
- Diseases
- Prostate cancer
- NCT number
- NCT06830408
What you commit to
- Study type: Observational
- Participants enrolled: 250
- From 6 Jul 2020 to the primary completion date, 12 Nov 2024
- 8 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- patients who are not eligible for PSMA RLT, according to current, standard medical indications and guidelines
- patients who for medical or non-medical reasons are unable to give their consent
- patients withdrawing their consent for participation (NB: the already collected data in such cases will be anonymized and further used for applicable analyses)
Who the study is looking for
- hormone-refractory and PSMA PET/CT-positive prostate tumors
- progressed after or are ineligible for chemotherapy, next-generation antihormonal therapy or bone-directed radiation therapy -- male patients with an age above 18 years
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (8)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Kantonspital Aarau Coordinator of this site? Confirm its status | Aarau | Switzerland | Unknown status |
| University Hospital Basel Coordinator of this site? Confirm its status | Basel | Switzerland | Unknown status |
| Inselspital Coordinator of this site? Confirm its status | Bern | Switzerland | Unknown status |
| CHUV Coordinator of this site? Confirm its status | Lausanne | Switzerland | Unknown status |
| St. Anna Hirslanden Klinik Coordinator of this site? Confirm its status | Lucerne | Switzerland | Unknown status |
| Luzerner Kantonsspital Coordinator of this site? Confirm its status | Lucerne | Switzerland | Unknown status |
| Kantonsspital St. Gallen Coordinator of this site? Confirm its status | Sankt Gallen | Switzerland | Unknown status |
| University Hospital Zurich Coordinator of this site? Confirm its status | Zurich | Switzerland | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.